Two Sigma Investments LP Lowers Stock Holdings in CytomX Therapeutics, Inc. (NASDAQ:CTMX)

Two Sigma Investments LP trimmed its position in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) by 32.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 320,767 shares of the biotechnology company’s stock after selling 150,701 shares during the quarter. Two Sigma Investments LP’s holdings in CytomX Therapeutics were worth $330,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of CTMX. Miller Financial Services LLC purchased a new position in CytomX Therapeutics during the 4th quarter valued at about $26,000. Monimus Capital Management LP purchased a new position in CytomX Therapeutics during the 4th quarter valued at about $375,000. Prudential Financial Inc. boosted its holdings in CytomX Therapeutics by 76.2% during the 4th quarter. Prudential Financial Inc. now owns 64,300 shares of the biotechnology company’s stock valued at $66,000 after acquiring an additional 27,800 shares during the period. JPMorgan Chase & Co. boosted its holdings in CytomX Therapeutics by 288,736.3% during the 4th quarter. JPMorgan Chase & Co. now owns 811,630 shares of the biotechnology company’s stock valued at $836,000 after acquiring an additional 811,349 shares during the period. Finally, Renaissance Technologies LLC boosted its holdings in CytomX Therapeutics by 32.7% during the 4th quarter. Renaissance Technologies LLC now owns 1,346,800 shares of the biotechnology company’s stock valued at $1,387,000 after acquiring an additional 331,800 shares during the period. 67.77% of the stock is currently owned by hedge funds and other institutional investors.

CytomX Therapeutics Stock Performance

Shares of CTMX opened at $2.70 on Wednesday. The stock has a 50-day simple moving average of $1.42 and a 200-day simple moving average of $1.06. The stock has a market capitalization of $217.68 million, a PE ratio of 15.88 and a beta of 2.11. CytomX Therapeutics, Inc. has a 1 year low of $0.40 and a 1 year high of $2.88.

CytomX Therapeutics (NASDAQ:CTMX) last issued its earnings results on Monday, May 12th. The biotechnology company reported $0.27 earnings per share for the quarter, topping the consensus estimate of $0.18 by $0.09. CytomX Therapeutics had a negative return on equity of 41.47% and a net margin of 10.96%. The business had revenue of $50.92 million for the quarter, compared to analyst estimates of $35.42 million. During the same quarter last year, the company earned $0.17 EPS. Analysts predict that CytomX Therapeutics, Inc. will post -0.05 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages recently commented on CTMX. Piper Sandler raised their target price on CytomX Therapeutics from $2.50 to $5.00 and gave the company an “overweight” rating in a report on Thursday, May 15th. Wall Street Zen upgraded CytomX Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, May 13th. HC Wainwright upgraded CytomX Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 price objective for the company in a research note on Thursday, May 15th. Finally, Wedbush reiterated an “outperform” rating and issued a $6.00 price objective (up previously from $5.00) on shares of CytomX Therapeutics in a research note on Monday, May 12th.

CytomX Therapeutics Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.